Current Status of Molecular Biomarkers in Endometrial Cancer

In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as w...

Full description

Saved in:
Bibliographic Details
Published in:Current oncology reports 2014-09, Vol.16 (9), p.403-403, Article 403
Main Authors: Werner, H. M. J., Salvesen, H. B.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
DNA, Neoplasm - genetics
Endometrial Neoplasms - diagnosis
Endometrial Neoplasms - genetics
Female
Genes, p53
Gynecologic Cancers (NS Reed
Humans
Medicine
Medicine & Public Health
Oncology
Ploidies
Predictive Value of Tests
Prognosis
Section Editor
Topical Collection on Gynecologic Cancers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In spite of the high and increasing incidence of endometrial cancer, our current models for prediction of prognosis and even more treatment response are suboptimal, and molecular biomarkers to assist clinical decision making are needed. In this review an overview is given of the currently known as well as promising prognostic and predictive biomarkers in endometrial carcinoma. Key clinical challenges, where use of molecular biomarkers can meet clinical needs, are highlighted. The current status for the presently most promising prognostic and predictive biomarkers in endometrial carcinoma is reviewed. DNA ploidy, p53 status, hormone receptor level, HER2, stathmin, L1 cell adhesion molecule expression and other biomarkers are discussed in relation to the scientific robustness of various essential steps in biomarker development and (current) clinical applicability for individualizing treatment strategies. Tumour heterogeneity and its consequences for biomarker assessment and the importance of developing standardised tests for implementation are discussed. To improve the development and clinical uptake of biomarkers, several strategies are proposed.
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-014-0403-3